Information Technology
A Decade of Cell & Gene Therapy Manufacturing and Major GMP Facility Expansion: Cellex's Track Record of Scalable Excellence
Founded in 2001 in Dresden by Prof. Dr. Gerhard Ehninger to secure sourcing of cellular therapies for patients in need of an allogeneic blood stem cell transplantation, Cellex has grown into one of Europe's leading CGT CDMOs, driven by a strong focus on patient access and operational excellence. In 2009, Cellex expanded to Cologne by opening a second collection center. Since then, the team performed over .
By 2013, the company extended its services to cover the entire value chain, ensuring further establishing its end-to-end manufacturing capability.
Since 2018, Cellex has supported the CGT supply chain with a donor database for R&D, clinical trials, and commercial programs, supplying GMP-grade starting materials such as Leukopaks, Mobilized Leukopaks, Whole Blood, and Bone Marrow.
From 2019 onward, Cellex undertook of its GMP infrastructure, integrating high-throughput cleanroom environments and quality control labs. With the latest facility expansion, the company operates , with 43% allocated to cleanroom operations across 37 workstations.
With manufactured - including Cellex has demonstrated consistent execution across the full development spectrum. The company currently manufactures six final drug products and seven cellular intermediates, and supports the commercial production of three CAR-T therapies approved in the EU. In 2023, Cellex successfully manufactured Europe's , reinforcing its role in cutting-edge therapy development.
"In the manufacturing of advanced therapies, innovation must be matched by a high degree of precision and reliability." says Carla Kreissig, Managing Director and Chief Medical Officer of Cellex. "Reaching over 5,800 batches reflects not just scale - but deep process maturity and trust from our partners. With our latest GMP facility expansion, we are further strengthening our capabilities to meet growing demand and ensure continued excellence."
Additionally, a new materials warehouse was launched this year. Designed to the highest standards, it ensures quality, safety, and efficiency for every batch. With expanded storage capacity, we are well equipped to meet the continuously growing demand in CGT manufacturing.
In 2014, Cellex entered the CGT field by launching its first preclinical and clinical development program focused on adapter CAR-T technology in Dresden. A dedicated manufacturing facility was established in Cologne to support PoC trials for academic and biotech partners.
Long-standing partnerships underscore the company's credibility and manufacturing maturity:
In January 2025 , Cellex Cell Professionals onboarded two new clients, with a robust pipeline of new mandates for the remainder of the year and beyond. With over 10 years of experience in autologous and allogeneic cell therapy and the ability to support clients from , Cellex Cell Professionals remains uniquely positioned among European CDMOs - defined not by capability alone, but by a proven record of execution.
Cellex Cell Professionals is a leading, full service CDMO specializing in CGT. With its state-of-the-art facilities located in Cologne, Germany , and a proven track record of 10+ years in GMP-compliant autologous and allogeneic cell therapy manufacturing, Cellex is partnered with several major pharma and innovative biotech companies supporting their process development and clinical and commercial manufacturing. In addition, Cellex offers customized starting materials from healthy donors and patients affected by specific conditions for research, clinical and commercial purposes as well as storage and logistics services.
Learn more at www.cellex.me/en.
Phone: +49 221 2509 0
E-mail: infocenter@cellex.me
Logo: https://mma.prnewswire.com/media/2621986/5352785/CelleLogo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/a-decade-of-cell--gene-therapy-manufacturing-and-major-gmp-facility-expansion-cellexs-track-record-of-scalable-excellence-302473126.html